Analysis of transferrin in urine in patients with bladder cancer using nanobodies

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

It is known that the saturation ratio of transferrin (Tf) with iron in human blood is an important clinical parameter. Specific antibodies can be used to analyze subtle changes in the relative abundance of different forms of transferrin potentially associated with a pathological process. Recently, the authors of this study were able to obtain and characterize highly specific single-domain antibodies (nanobodies) that predominantly recognize the iron-saturated (holo-Tf) or iron-unsaturated (apo-Tf) form of transferrin. In this work, under conditions closer to physiological than in previous experiments, we further demonstrated that these unique nanobodies have extremely high differential binding specificity for different forms of Tf in different human biological fluids. Using these nanobodies, we were able to analyze for the first time the relative abundance of transferrin forms in urine samples from patients with bladder cancer (BC). We have shown that an increase in the concentration of total Tf in urine samples normalized for creatinine is associated with the degree of progress and growth of malignancy of BC. In the samples of healthy donors and in the early stages of BC (G1), Tf is detected in much smaller amounts (compared to later stages) and only with additional concentration of the studied samples. For most of the studied urine samples from BC patients, it is expected (as previously shown in the case of Tf in the blood of terminal ovarian cancer patients) that the concentration of apo-Tf is clearly higher than holo-Tf, especially in the case of the most advanced muscle-invasive BC. It was a surprise for us that approximately equal amounts of apo-Tf and “holo-Tf” were found in the urine samples of some patients with BC. We hypothesized that the “holo-Tf” fraction in this case can be largely represented by “secondary complexes” formed by apo-Tf in combination with ions other than Fe3+, which accumulate in the urine of some cancer patients and are able to bind to apo-Tf, changing its conformation towards holo-Tf. Using inductively coupled plasma ionization mass spectroscopy (ICP-MS), we obtained the first results confirming our hypothesis. The “holo-Tf” preparation in these urine samples was found to be highly enriched in zinc and nickel. Also in this preparation, a relative enrichment in cadmium is observed, but it is present in much lower concentrations. The data obtained indicate that the nanobody used, recognizing predominantly the iron-saturated form of transferrin (holo-Tf), is also capable of binding transferrin in association with other metal ions that are different from iron. This ability could potentially open up new possibilities in studies of the relative abundance of various metal ions in association with transferrin in human biological fluids in normal and pathological conditions.

About the authors

A. M Sachko

Institute of Gene Biology, Russian Academy of Sciences

119334 Moscow, Russia

O. S Goryainova

Institute of Gene Biology, Russian Academy of Sciences

119334 Moscow, Russia

T. I Ivanova

Institute of Gene Biology, Russian Academy of Sciences;Tsyb Medical Radiological Research Centre - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

119334 Moscow, Russia;249036 Obninsk, Russia

I. Yu Nikolaeva

Faculty of Geology, Lomonosov Moscow State University

119234 Moscow, Russia

M. E Tarnopolskaia

Faculty of Geology, Lomonosov Moscow State University

119234 Moscow, Russia

A. Yu Bychkov

Faculty of Geology, Lomonosov Moscow State University

119234 Moscow, Russia

M. Ya Gaas

Peoples’ Friendship University of Russia (RUDN University)

117198 Moscow, Russia

N. V Vorob'ev

Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

125284 Moscow, Russia;119991 Moscow, Russia

A. D Kaprin

Peoples’ Friendship University of Russia (RUDN University);National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

117198 Moscow, Russia;125284 Moscow, Russia

References

  1. Torti, S. V., and Torti, F. M. (2020) Iron: the cancer connection, Mol. Aspects Med., 75, 100860, doi: 10.1016/j.mam.2020.100860.
  2. Candelaria, P. V., Leoh, L. S., Penichet, M. L., and Daniels-Wells, T. R. (2021) Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents, Front. Immunol., 12, 607692, doi: 10.3389/fimmu.2021.607692.
  3. Yiannikourides, A., and Latunde-Dada, G. O. (2019) A short review of iron metabolism and pathophysiology of iron disorders, Medicines (Basel), 6, 85, doi: 10.3390/medicines6030085.
  4. Ramírez-Carmona, W., Díaz-Fabregat, B., Yuri Yoshigae, A., Musa de Aquino, A., Scarano, W. R., de Souza Castilho, A. C., Avansini Marsicano, J., Leal do Prado, R., Pessan, J. P., and de Oliveira Mendes, L. (2022) Are serum ferritin levels a reliable cancer biomarker? A systematic review and meta-analysis, Nutr. Cancer, 74, 1917-1926, doi: 10.1080/01635581.2021.1982996.
  5. Szőke, D., and Panteghini, M. (2012) Diagnostic value of transferrin, Clin. Chim. Acta, 413, 1184-1189, doi: 10.1016/j.cca.2012.04.021.
  6. Ivanova, T. I., Klabukov, I. D., Krikunova, L. I., Poluektova, M. V., Sychenkova, N. I., Khorokhorina, V. A., Vorobyev, N. V., Gaas, M. Ya., Baranovskii, D. S., Goryainova, O. S., Sachko, A. M., Shegay, P. V., Kaprin, A. D., and Tillib, S. V. (2022) Prognostic value of serum transferrin analysis in patients with ovarian cancer and cancer-related functional iron deficiency: a Retrospective case-control study, J. Clin. Med., 11, 7377, doi: 10.3390/jcm11247377.
  7. Elsayed, M. E., Sharif, M. U., and Stack, A. G. (2016) Transferrin saturation: a body iron biomarker, Adv. Clin. Chem., 75, 71-97, doi: 10.1016/bs.acc.2016.03.002.
  8. Tillib, S. V., Goryainova, O. S., Sachko, A. M., and Ivanova, T. I. (2022) High-affinity single-domain antibodies for analyzing human apo- and holo-transferrin, Acta Naturae, 14, 98-102, doi: 10.32607/actanaturae.11663.
  9. Тиллиб С. В, Горяйнова О. С., Сачко А. М., Иванова Т. И., Гаас М. Я., Воробьев Н. В., Каприн А. Д., Шегай П. В. (2022) Однодоменные антитела для предобработки протеома мочи человека с целью анализа онкобиомаркеров, Молекулярная биология, 56, 671-684.
  10. Nowakowski, A. B., Wobig, W. J., and Petering, D. H. (2014) Native SDS-PAGE: high resolution electrophoretic separation of proteins with retention of native properties including bound metal ions, Metallomics, 6, 1068-1078, doi: 10.1039/c4mt00033a.
  11. Wessel, D., and Fluegge, U. I. (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids, Anal. Biochem., 138, 141-143, doi: 10.1016/0003-2697(84)90782-6.
  12. Wang, F., Chmil, C., Pierce, F., Ganapathy, K., Gump, B. B., MacKenzie, J. A., Metchref, Y., and Bendinskas, K. (2013) Immobilized metal affinity chromatography and human serum proteomics, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 934, 26-33, doi: 10.1016/j.jchromb.2013.06.032.
  13. Hochstrasser, D. F., Patchornik, A., and Merril, C. R. (1988) Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining, Anal. Biochem., 173, 412-423, doi: 10.1016/0003-2697(88)90208-4.
  14. Luo, J., Solimini, N. L., and Elledge, S. J. (2009) Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823-837, doi: 10.1016/j.cell.2009.02.024.
  15. Zapién Serrano, L. Z., Ortiz Lara, N. O., Ríos Vera, R. R., and Cholico-González, D. (2021) Removal of Fe(III), Cd(II), and Zn(II) as hydroxides by precipitation-flotation system, Sustainability, 13, 11913, doi: 10.3390/su132111913.
  16. Vincent, J. B., and Love, S. (2012) The binding and transport of alternative metals by transferrin, Biochim. Biophys. Acta, 1820, 362-378, doi: 10.1016/j.bbagen.2011.07.003.
  17. Williams, J., and Moreton, K. (1980) The distribution of iron between the metal-binding sites of transferrin human serum, Biochem. J., 185, 483-488, doi: 10.1042/bj1850483.
  18. Sun, H., Li, H., and Sadler, P. J. (1999) Transferrin as a metal ion mediator, Chem. Rev., 99, 2817-2842, doi: 10.1021/cr980430w.
  19. Benjamín-Rivera, J. A., Cardona-Rivera, A. E., Vázquez-Maldonado, Á. L., Dones-Lassalle, C. Y., Pabón-Colon, H. L., Rodríguez-Rivera, H. M., Rodríguez, I., González-Espiet, J. C., Pazol, J., Pérez-Ríos, J. D., Catala-Torres, J. F., Carrasquillo Rivera, M., De Jesus-Soto, M. D., Cordero-Virella, N. A., Cruz-Maldonado, P. M., González-Pagan, P., Hernández-Ríos, R., Gaur, K., Loza-Rosas, S. A., and Tinoco, A. D. (2020) Exploring serum transferrin regulation of nonferric metal therapeutic function and toxicity, Inorganics, 8, 48, doi: 10.3390/inorganics8090048.
  20. Chang, C. H., Liu, C. S., Liu, H. J., Huang, C. P., Huang, C. Y., Hsu, H. T., Liou, S. H., and Chung, C. J. (2016) Association between levels of urinary heavy metals and increased risk of urothelial carcinoma, Int. J. Urol., 23, 233-239, doi: 10.1111/iju.13024.

Copyright (c) 2023 Russian Academy of Sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies